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Purpose: Prospective single-center study to assess the sensitivity and clinical relevance of
molecular testing for respiratory viruses in critically ill immunocompromised patients with
acute respiratory failure (ARF).
Methods: 100 consecutive critically ill immunocompromised patients with ARF in 2007e2009.
Among them, 65 had hematologic malignancies (including 14 hematopoietic stem cell trans-
plant recipients), 22 had iatrogenic immunosuppression, and 13 had solid malignancies. A
multiplex molecular assay (MMA) was added to the usual battery of tests performed to look
for causes of ARF.
Results: Nasopharyngeal aspirates and/or bronchoalveolar lavage fluid were tested for respi-
ratory viruses using both the MMA and immunofluorescence. A virus was detected in 47 (47%)
patients using the MMA and 8 (8%) patients using immunofluorescence (P Z 0.006). MMA-
positive and MMA-negative patients had similar clinical and radiographic presentations and
were not significantly different for the use of ventilatory support (58% vs. 76%, P Z 0.09),
occurrence of shock (43% vs. 53%, P Z 0.41), use of renal replacement therapy (26% vs.
23%, P Z 0.92), SAPS II (35 [26e44] vs. 38 [27e50], P Z 0.36), time spent in the ICU (6 vs. 7ailure; BAL, bronchoalveolar lavage; CI, confidence interval; hMPV, human metapneumovirus; HSCT,
tion; ICU, intensive care unit; IQR, interquartile range; MMA, multiplex molecular assay; MLPA,
mplification; NA, not available; NPA, nasopharyngeal aspirate; OR, odds ratio; PCR, polymerase chain
, respiratory syncytial virus; RV, respiratory virus; SAPS II, simplified acute physiology score II.
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Respiratory viruses in immunocompromised ICU patients 1185days, PZ 0.35), or ICU mortality (17% vs. 28%, PZ 0.27). Using MMA, a virus was found in 6 of
the 12 patients with no diagnosis at the end of the etiologic investigations.
Conclusions: In critically ill immunocompromised patients, an MMA was far more sensitive than
immunofluorescence for respiratory virus detection. Patients with RVs detected in the respira-
tory tract had the same clinical characteristics and outcomes as other patients.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
Acute respiratory failure (ARF) occurs in up to 50% of
patients with malignancies, who are then at high risk for
death, particularly if they require mechanical ven-
tilation.1e4 Respiratory viruses (RVs) are detected in 10%e
20% of these ARF episodes.5,6 Together with the bacterial
and fungal infections often seen in this setting, RV infec-
tions are potentially life-threatening in immunocompro-
mised patients.7e11
Viral culture has long been considered the reference
standard for diagnosing RV infection but usually takes
several days to yield results. Antigen detection is faster but
less sensitive.12 Molecular screening based on the poly-
merase chain reaction (PCR) is fast, more sensitive than
earlier test methods, highly specific, and capable of
detecting rhinoviruses and coronaviruses, which are missed
by other tests.13 Molecular assays have been reported to
improve the diagnostic yield compared with conventional
methods during acute respiratory illnesses in patients with
hematological malignancies.14e17 However, they detect
only nucleic acids, as opposed to live organisms, and their
clinical relevance is therefore unclear. A positive molecular
assay on a respiratory sample may indicate viral infection,
colonization, or contamination.
The purpose of this study was to evaluate a multiplex
molecular assay (MMA) comparatively with immunofluores-
cence for RV detection in immunocompromised patients
admitted to intensive care unit (ICU) with ARF and to assess
the clinical relevance of the MMA results.
Patients and methods
Immunocompromised patients with hypoxemic ARF
admitted to our closed ICU in a teaching hospital from
January 2007 to July 2009 were included prospectively in
this cohort study. The MMA was the intervention. The
institutional review board of the Clermont Ferrand teaching
hospital approved this study and waived the need for
informed consent.
Immunocompromised status was defined as presence of
a disease or treatment known to impair the immune
system, such as a hematological or metastatic solid malig-
nancy or long-term corticosteroid therapy, immunosup-
pressive therapy, cytotoxic chemotherapy, and/or bone
marrow or hematopoietic stem cell transplantation (HSCT).
Patients infected with the human immunodeficiency virus
were not included.
ARF was defined as a respiratory rate greater than 30
breaths per minute or respiratory distress symptoms orPaO2 on room air lower than 8 kPa or a need for ventilatory
support.
The data reported in Tables 1e3 were collected for each
study patient. Simplified acute physiology score II (SAPS II),
time in the ICU and vital status at ICU discharge were also
collected.18
All patients were investigated using a previously
described diagnostic strategy that relies heavily on nonin-
vasive tests.19 Most of the patients underwent noninvasive
tests for infections, such as sputum examination for
bacteria, mycobacteria, and fungi; induced sputum for
Pneumocystis jirovecii pneumonia; serum and blood tests
for circulating Cytomegalovirus and Aspergillus; blood
cultures; specific PCR tests for herpes viruses on blood and
respiratory samples; and urine tests for bacterial antigens.
Bronchoscopy and bronchoalveolar lavage (BAL) were per-
formed when deemed appropriate by the attending physi-
cian. BAL fluid was collected as previously described19 and
was used for bacterial, mycobacterial, and fungal cultures;
RV antigen detection by immunofluorescence; and cyto-
logical examination. Echocardiography, chest computed
tomography, and thoracocentesis were also performed
when deemed appropriate by the attending physician.
Clinically documented infection was defined as a strong
clinical and radiographic suspicion of pneumonia without
microbiological documentation but with either septic shock
or complete resolution after antibacterial treatment.5
Immunofluorescence (Argene, Verniolle, France) was
performed routinely to test nasopharyngeal aspirates (NPA)
and BAL fluid for influenza A and B viruses; respiratory
syncytial virus (RSV); parainfluenza viruses (PIV) 1, 2, and 3;
and adenoviruses. Human metapneumovirus (hMPV) was
sought starting in October 2007.
All respiratory specimens were also investigated for RVs
using an MMA based on the Multiplex Ligation-dependent
Probe-Amplification (MLPA) technology (RespiFinder19,
Pathofinder, Maastricht, The Netherlands) that allows the
detection and differentiation of 14 respiratory viruses,
including influenza viruses A and B; PIV-1 to PIV-4; RSV A
and B; rhinovirus; human coronaviruses 229E, OC43 and
NL63; hMPV; and adenovirus.20 Additionally, this MMA
detects influenza A H5N1 and four bacteria (Chlamydophila
pneumoniae, Mycoplasma pneumoniae, Legionella pneu-
mophila, and Bordetella pertussis). Samples were stored at
80c. Before extraction, 5 ml of an internal amplification
control which contained an encephalomyocarditis virus RNA
transcript was added into the sample. Nucleic acids were
purified from 400 ml of samples with the EasyMag system
(Biom » rieux, Marcy l’Etoile, France) and eluted in 100 ml
of elution buffer, of which 10 were used for amplification.
The three steps of pre-amplification, hybridization and
Table 1 Baseline characteristics, symptoms, chest radiography patterns, need for life-supporting interventions, and
outcomes of the 100 immunocompromised patients with acute respiratory failure and comparaison of patients with and without
a positive MMA.
Characteristics Total Positive MMA Negative MMA P value OR (95%CI)
Patients 100 47 53 / /
65 (65%) 29 (62%) 36 (68%)
Male/Female / / / 0.66 0.76 (0.33e1.73)b
35 (35%) 18 (38%) 17 (32%)
Agea 60 (44e67) 58 (41e67) 60 (46e67) 0.45 0.99 (0.97e1.01)
Community-acquired ARFc 43 (43%) 22 (47%) 21 (40%) 0.6 1.34 (0.61e2.97)
Immunosuppressants in
the past month
76 (76%) 40 (85%) 36 (68%) 0.05 2.7 (1.0e7.25)
Corticosteroids in the past month 39 (39%) 21 (45%) 18 (34%) 0.36 1.6 (0.71e3.64)
Underlying disease
Hematological malignancy 65 (65%) 29 (62%) 36 (68%) 0.66 0.76 (0.33e1.73)
Lymphoma 28 (28%) 14 (30%) 14 (26%) 0.88 1.18 (0.49e2.83)
Acute lymphocytic leukemia 5 (5%) 2 (4%) 3 (6%) 0.99 0.74 (0.12e4.64)
Acutemyelogenous leukemia 16 (16%) 6 (12%) 10 (18%) 0.58 0.63 (0.21e1.89)
Chronic lymphocytic leukemia 4 (4%) 1 (2%) 3 (6%) 0.7 0.36 (0.04e3.61)
Chronicmyelogenous leukemia 4 (4%) 1 (2%) 3 (6%) 0.7 0.36 (0.04e3.61)
Myeloma 8 (8%) 6 (12%) 2 (4%) 0.2 3.73 (0.72e19.5)
Myelodysplastic disorder 1 (1%) 0 (0%) 1 (2%) 0.99 /
HSCT 14 (14%) 9 (19%) 5 (9%) 0.27 2.27 (0.7e7.35)
Iatrogenic immunosuppression 22 (22%) 14 (30%) 8 (15%) 0.13 2.39 (0.9e6.35)
Solid organ transplantation 16 (16%) 12 (26%) 4 (7.5%) 0.03 4.2 (1.25e14.1)
Autoimmune disorders 6 (6%) 2 (4%) 4 (7.5%) 0.79 0.54 (0.1e3.12)
Solid tumors 13 (13%) 4 (8%) 9 (17%) 0.34 0.46 (0.13e1.59)
Metastatic solid tumor 7 (7%) 2 (4%) 5 (9%) 0.54 0.43 (0.08e2.31)
Symptoms
Fever 61 (61%) 31 (66%) 30 (57%) 0.45 1.49 (0.66e3.35)
Cough 49 (49%) 32 (68%) 24 (46%) 0.07 2.5 (0.99e6.1)
General symptomsd 8 (8%) 5 (11%) 3 (6%) 0.59 1.98 (0.35e8.8)
Purulent sputum 14 (14%) 8 (17%) 6 (11%) 0.6 1.61 (0.51e5.02)
Chest radiography patterns
Normal 11 (11%) 7 (15%) 4 (8%) 0.39 2.1 (0.59e7.85)
Lobar alveolar consolidation 16 (16%) 9 (19%) 7 (16%) 0.59 1.56 (0.53e4.57)
Diffuse alveolar consolidation 48 (48%) 23 (49%) 25 (47%) 0.99 1.1 (0.49e2.36)
Interstitial involvement 41 (41%) 22 (47%) 19 (36%) 0.36 1.58 (0.71e3.51)
Pleural effusion 2 (14%) 2 (4%) 0 (0%) 0.53 /
Life-supporting interventions
and outcomes
Mechanical ventilation 67 (67%) 27 (58%) 40 (76%) 0.09 0.44 (0.19e1.03)
Shock 48 (48%) 20 (43%) 28 (53%) 0.41 0.66 (0.3e1.46)
Renal replacement therapy 24 (24%) 12 (26%) 12 (23%) 0.92 1.17 (0.47e2.94)
SAPS II 36 (27e46) 35 (26e44) 38 (27e50) 0.36 0.99 (0.96e1.02)
Time spent in the ICUe 7 (3e13) 6 (2e13) 7 (3e17) 0.35 0.99 (0.96e1.02)
ICU mortality 23 (23%) 8 (17%) 15 (28%) 0.27 0.52 (0.2e1.37)
Data are number (percent), unless otherwise stated. Results are from the univariate analysis.
ARF, acute respiratory failure; HSCT, human stem cell transplantation; ICU, intensive care unit; MMA, multiplex molecular assay; OR,
odds ratio; 95%CI, 95% confidence interval; SAPS II: simplified acute physiology score II.
a Years, median (interquartile range).
b For men.
c Episode of acute respiratory failure beginning outside the hospital.
d General symptoms: asthenia, myalgia, and headache.
e Days, median (interquartile range).
1186 D. Schnell et al.ligation-PCR were performed on a C1000 themocycler (Bio-
Rad, Marnes la Coquette, France). The amplified MLPA
products were analyzed on an ABI 3100 genetic analyzer
(Applied Biosystems, Foster City, CA). Fragment sizinganalysis was performed with the GeneMarker software
(SoftGenetics, LLC, State College, PA).
Two clinicians reviewed the medical charts of all study
patients to determine theetiologies of ARF.Thiswasmadeon
Table 2 Results of immunofluorescence and a multiplex
molecular assay for respiratory viruses.
Variables Immunofluorescence MMA P value
Influenza All 2 14 0.012
A 2 11 0.0035
B 0 3 /
RSV 3 4 0.99
PIV All 1 6 0.063
1 NA 0 /
2 NA 1 /
3 NA 4 /
4 NA 1 /
hMPV 1 6 0.063
Adenovirus 1 4 0.018
Rhinovirus 0 15 /
Coronavirus 0 3 /
All virus 8 52 /
All patients 8 (8%) 47 (47%) 0.006
Data are number (percent). Results are from the univariate
analysis.
MMA, multiplex molecular assay; hMPV, human meta-
pneumovirus; NA, not available; PIV, parainfluenza virus; RSV,
respiratory syncytial virus.
Respiratory viruses in immunocompromised ICU patients 1187the basis of clinical, radiographic, microbiological, and
histological findings, according to predefined criteria.1,6,21
The reviewers also aimed at evaluating the clinical signifi-
cance of RV detection by MMA in these patients. In the
absence of validated criteria, this was mainly based on the
presence or absence of a definite etiology of ARF, and on the
possible interplay between viral infection and this etiology.
Statistics
Quantitative parameters are reported as median and inter-
quartile range (IQR, 25th 75th percentiles) and qualitative
parameters as number andpercentage.Categorical variables
were compared using the c2 test or Fisher’s exact test, as
appropriate. Continuous variables were compared using the
ManneWhitney U test or the Wilcoxon test, as appropriate.
Associations between patient characteristics and positive
MMA results were assessed using a logistic regression model.
Multivariable analysis was performed using stepwise forward
selection to introduce variables yielding P values smaller
than 0.20 by univariate analysis. We also introduced vari-
ables that seemed clinically relevant. Then, the absence of
a significant increase in the likelihood value after omission of
each of the remaining variables was checked. Odds ratios
(ORs) and their 95% confidence intervals (95%CIs) were
computed. P values less than 0.05 were considered signifi-
cant. Statistical analyses were performed using Statview 5.0
(SAS Institute, Cary, NC).Results
We included 100 immunocompromised patients admitted to
our ICU with ARF during the study period. Their maincharacteristics are listed in Table 1. Median symptom
duration at ICU admission was 31e6 days. The admission
leukocyte count was 7.7 (3.4e14.9) 109 L1, and 6 (6%)
patients had neutropenia at admission. At admission, PaO2
was 11.3 (8.7e14.6) kPa with a mean oxygen rate of 62e12
L$min1, PaCO2 was 4.88 (4.00e5.9) kPa, and pH was 7.42
(7.37e7.46). The use of life-supporting interventions and
outcomes over time are reported in Table 1.
TheMMAwas performed onNPA in 45 (45%) patients and BAL
fluid in 55 (55%). Immunofluorescence was positive in 8 (8%)
patients and theMMA in 47 (47%) patients (PZ 0.006) (Table 2).
After excluding rhinoviruses and coronaviruses, the difference
remained highly significant (31% versus 8%, P < 0.0001). Co-
infection with two viruses was detected in 5 patients using
the MMA; the combinations were influenza A and rhinovirus,
influenza A and hMPV, influenza A and adenovirus, influenza B
and adenovirus, and PIV 2 and coronavirus OC43.
Table 1 compares patients with and without a positive
MMA. At ICU admission, there were no significant differences
in symptom duration (4 [2e7] days vs. 3 [1e6] days, respec-
tively; PZ 0.23), PaO2 (11 [8.8e15.4] kPa vs. 11.4 [8.5e14],
respectively; PZ 0.47), PaCO2 (5.2 [4.0e5.9] mmHg vs. 4.7
[4.0e5.9], respectively; PZ 0.31), pH (7.41 [7.36e7.45] vs.
7.44 [7.37e7.46], respectively; P Z 0.36), or leukocyte
count (8.0 [3.1e14.0] 109 L1 vs. 7.2 [3.6e15.6]109 L1,
respectively; P Z 0.67). By univariate analysis, a positive
MMA was associated with being a solid organ transplant
recipient (P Z 0.01), receiving immunosuppressants in the
pastmonth (PZ 0.05), and being tested on NPA (60% vs. 32%,
P Z 0.01). No variable was significantly associated with
a positive MMA by multivariate analysis.
Study patients were classified into diagnostic categories
based on a medical chart review (Fig. 1). The MMA was
positive in 30 of the 48 patients with lung infections and 17
of the 52 patients with non-infectious lung diseases. Results
of microbial investigations are given in Table 3. Co-
infections with an RV and bacteria or fungi were found in
11 patients with infectious lung disease. These co-
infections are described in Table 4. All patients were
considered as having bacterial or fungal lung infection. A
patient with non-infectious lung disease had a respiratory
sample positive with coagulase-negative Staphylococci and
coronavirus NL63. These pathogens were not considered
significant. Also, Table 3 compares the MMA-positive and
MMA-negative patients in the subgroups with and without
lung infection. In the subgroup of patients with non-
infectious lung diseases, 12 patients had no diagnosis
found at the end of the etiologic investigations. Multiplex
molecular assay was positive in 6 (50%) of these patients.Discussion
Among immunocompromised patients admitted to the ICU
with ARF, about half had an RV detected by MMA, which was
more than 5-fold the rate of RV detection by immunofluo-
rescence. The MMA still had a significantly higher sensitivity
when we considered only the viruses included in the
immunofluorescence panel. All viruses detected by immu-
nofluorescence were also detected by the MMA.
To our knowledge, this is the first MMA study in immu-
nocompromised patients with ARF. About half these
Table 3 Microorganisms, use of life-supporting interventions, and outcomes in patients with and without documented lung
infections and in patients with and without a positive MMA for respiratory viruses.
Total Positive MMA Negative MMA P value OR (95%CI)
Documented lung infection 48 30 18 / /
Clinically documented infection 29 (60%) 19 (63%) 10 (56%) 0.82 1.4 (0.42e4.5)
Microorganisms in respiratory specimensb 19 (40%) 11 (37%) 8 (44%) 0.59 0.72 (0.22e2 0.4)
Bacteria 11 (23%) 5 (17%) 6 (33%) / /
Streptococcus pneumoniae 2 (4%) 1 (3%) 1 (5%) / /
Staphylococcus aureus 2 (4%) 2 (7%) 0 / /
Haemophilus influenzae 1 (2%) 0 1 (5%) / /
Enterobacteriaceae 2 (4%) 1 (3%) 1 (5%) / /
Pseudomonas aeruginosa 3 (7%) 1 (3%) 2 (11%) / /
Acinetobacter baumanii 1 (2%) 0 1 (5%) / /
Fungus 8 (17%) 6 (20%) 2 (11%) / /
Pneumocystis jirovecii 5 (10%) 4 (13%) 1 (5%) / /
Aspergillus sp. 3 (7%) 2 (7%) 1 (5%) / /
Mechanical ventilation 33 (69%) 20 (66%) 13 (72%) 0.69 0.77 (0.21e2.8)
Shock 30 (63%) 17 (57%) 13 (72%) 0.29 0.5 (0.14e1.8)
Duration of shocka 2 (0e3) 1 (0e3) 3 (0e4) 0.56 0.93 (0.74e1.2)
Renal replacement therapy 14 (29%) 11 (37%) 3 (17%) 0.15 2.9 (0.68e12.3)
Time spent in the ICUa 8 (4e16) 8 (4e13) 8 (3e17) 0.81 0.99 (0.96e1.0)
ICU mortality 13 (27%) 7 (23%) 6 (33%) 0.45 0.61 (0.17e2.2)
Non-infectious lung disease 52 17 35 / /
Clinically documented infection 0 0 0 / /
Microorganisms identified in
respiratory specimenb
4 (8%) 1 (6%) 3 (9%) 0.73 0.67 (0.06e6.9)
Bacteria 3 (6%) 1 (6%) 3 (9%) / /
Coagulase-negative 1 (2%) 1 (6%) 0 / /
Staphylococci
Enterobacteriaceae 1 (2%) 0 1 (3%) / /
Pseudomonas aeruginosa 1 (2%) 0 1 (3%) / /
Cytomegalovirus 1 (2%) 0 1 (3%) / /
Mechanical ventilation 34 (65%) 7 (41%) 27 (77%) 0.013 0.21 (0.06e0.72)
Shock 18 (35%) 3 (18%) 15 (43%) 0.08 0.29 (0.07e1.2)
Duration of shocka 0 (0e2) 0 (0e0) 0 (0e3) 0.008 /
Renal replacement therapy 10 (19%) 1 (6%) 9 (26%) 0.12 0.18 (0.02e1.6)
Time spent in the ICUa 6 (3e10) 4 (2e9) 7 (3e11) 0.07 0.91 (0.81e1.0)
ICU mortality 10 (19%) 1 (6%) 9 (26%) 0.12 0.18 (0.02e1.6)
Data are number (percent), unless otherwise stated. Results are from the univariate analysis.
ICU, intensive care unit; MMA, multiplex molecular assay; OR, odds ratio; 95%CI, 95% confidence interval.
a Days, median (interquartile range).
b Any bacterial, viral, and/or fungal agent identified in a respiratory specimen.
1188 D. Schnell et al.patients had at least one RV detected by the MMA. This high
sensitivity is consistent with the results of previous studies
in HSCT recipients with acute respiratory illnesses.15,16 Not
surprisingly, rhinoviruses were the RVs most commonly
detected by the MMA in our population.15,16,22 Rhinoviruses
and coronaviruses are not detected by immunofluores-
cence, a fact that may explain the higher sensitivity of the
MMA. However, the MMA remained significantly more
sensitive than immunofluorescence when we considered
only the RVs detected by both methods.
Whether the higher sensitivity of RV by molecular
screening improves the etiologic diagnosis of ARF remains
uncertain. The significance of a positive MMA in immuno-
compromised patients with ARF cannot be determined fromour data. In our study cohort, the need for life-supporting
interventions and the mortality rate were both low in MMA-
positive patients, but neither was significantly different
from that in MMA-negative patients. The clinical and
radiographic presentations were also similar. A positive
MMA with negative results of other tests for viruses has
been associated with lower viral loads and fewer respira-
tory symptoms compared to concomitant detection by MMA
and other tests. Thus, PCR-based methods may help to
detect asymptomatic or mildly symptomatic stages of RV
infections.14 Studies have established that RVs including
PIV, hMPV, and rhinoviruses are sometimes detected by
MMA in respiratory samples from symptom-free HSCT,
indicating that asymptomatic RV shedding can occur.16,17,23
Figure 1 Multiplex molecular assay results according to the
cause of acute respiratory failure.
Respiratory viruses in immunocompromised ICU patients 1189RV shedding lasts longer in immunocompromised patients
than in immunocompetent patients,17,24e26 and a positive
MMA may merely indicate a low level of shedding of limited
clinical significance. Therefore, in some of our patients,
a positive MMA may have indicated asymptomatic shedding
unrelated to the cause of the ARF. Finally, MMAs detect only
the nucleic acids of RVs, so that a positive MMA can be
related to sample contamination.
In the subgroup of patients without documented lung
infections, a positive MMA was associated with significantly
less use of mechanical ventilation, a significantly shorter
duration of hemodynamic failure, and nonsignificantly
lower values for use of renal replacement therapy, time in
the ICU, and ICU mortality. Thus, in immunocompromised
patients with ARF, the MMA may identify patients with
probable viral pulmonary involvement, a diagnosisTable 4 Co-infection with a respiratory virus and bacteria or fu
Bacteria or fungus
Patients with infectious lung disease
Patient 1 Escherichia coli
Patient 2 Staphylococcus aureus
Patient 3 Staphylococcus aureus
Patient 4 Pseudomonas aeruginosa
Patient 5 Streptococcus pneumoniae
Patient 6 Pneumocystis jirovecii
Patient 7 Aspergillus sp.
Patient 8 Pneumocystis jirovecii
Patient 9 Aspergillus sp.
Patient 10 Pneumocystis jirovecii
Patient 11 Pneumocystis jirovecii
Patient with non-infectious lung disease
Patient 1 Coagulase-negative Staphylococci
MMA, multiplex molecular assay; PIV, parainfluenza virus; RSV, respirassociated with better outcomes than those assumed to be
present when all tests are inconclusive. Indeed, negative
tests for the cause of ARF constitute a major diagnostic
criterion for severe non-infectious conditions such as drug-
related pulmonary toxicity or pulmonary infiltration by the
malignancy. Consequently, MMA may deserve to be added
to the list of investigations performed routinely to detect
the cause of ARF. Isn’t so, every effort should be done to
make the difference between a positive test and a diag-
nostic test. In contrast, in the subgroup of patients with
lung infections, there were no significant differences
between MMA-positive and MMA-negative patients. When
there is a known bacterial or fungal lung infection, identi-
fying an RV probably has no major impact on the manage-
ment strategy or patient outcome. An RV may act merely as
a risk factor for other infections or play a role in generating
ARF, either alone or in conjunction with a bacterial or
fungal infection.
Finally, the higher sensitivity of MMA compared to
immunofluorescence seems to have only limited clinical
consequences. The high frequency of RVs detection does
not appear to have significant impact on patients’
presentation and outcomes. This may be particularly true
in our cohort of critically ill patients. To gain insight into
the clinical significance of a positive MMA, routinely per-
forming the MMA on both BAL fluid and NPA and/or
obtaining lung biopsies might have been of interest.
Histology can show a cytopathic effect but lacks sensi-
tivity. Positive results are difficult to interpret, and no
criteria are available for determining the causal role for
the RV in the lung disease. High viral loads are more often
accompanied with clinical disease, but low viral loads do
not exclude clinical disease due to the virus. Moreover, the
pathogenesis of viral infection depends not only on
intrinsic viral pathogenicity, but also on genetic host
factors such as those involved in the immune response. For
rhinoviruses in particular, the clinical manifestations may
reflect the immune response to the infection rather than
the viral cytopathic effect.27ngi in patients with and without infectious lung disease.
RV detected by MMA Immunofluorescence
PIV-3 Negative
PIV-2 and coronavirus OC43 Negative
Adenovirus Negative
Influenza B Negative
Adenovirus Negative
Rhinovirus Negative
RSV Positive
Rhinovirus Negative
Rhinovirus Negative
Rhinovirus Negative
Rhinovirus Negative
Coronavirus NL63 Negative
atory syncytial virus.
1190 D. Schnell et al.Conclusion
In our prospective cohort of immunocompromised patients
admitted to the ICU with ARF, an MMAwas far more sensitive
than immunofluorescence for RV detection. The clinical
characteristics and outcomeswerenot significantly different
between MMA-positive and MMA-negative patients.
However, the MMA can suggest alternative diagnoses to non-
infectious lung diseases. Studies evaluating how this diag-
nostic strategy translates into improved diagnostic efficacy
with further increased survival are warranted.
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